Medicare Part D Coverage Gap Discount Proposal Challenged In Study
Analysis sponsored by a biopharma-backed group challenges MedPAC proposal for changing Part D procedures in a way that could reduce beneficiary incentives to choose high-cost branded drugs while in the coverage gap.
You may also be interested in...
Advisory group’s cost control recommendations on reinsurance, partial fills, and preferred specialty tiers could end up on the legislative agenda, particularly if Hillary Clinton is president.
Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.